Trial Profile

Clofarabine Bone Marrow Cytoreduction : Feasibility of Induction as a Bridge to Allogeneic Stem Cell Transplantation for Patients With Relapsed or Refractory Acute Leukemias, Myelodysplastic Syndromes, and Advanced Myeloproliferative Diseases.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 09 May 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Clofarabine (Primary)
Indications Leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
Focus Therapeutic Use

30 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
01 Sep 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
09 Oct 2009 Genzyme Corporation added as trial sponsor and lead trial centre as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com